The Neurogenomics Laboratory aims to uncover the cell types and epigenetic targets of human genetic risk for substance use and substance use disorder by combining a computational, big data approach with new experimental technologies to manipulate the genome. We apply a comparative the conserved epigenomic landscapes of neural cell types using machine learning to understand which human variants affect which cell types and how we might investigate their roles in behaving model organisms.
Srinivasan C*, Phan BN*, Lawler AJ, Ramamurthy E, Kleyman M, Brown AR, Kaplow IM, Wirthlin ME, Pfenning AR, “Addiction-associated genetic variants implicate brain cell type- and region-specific cis-regulatory elements in addiction neurobiology”. Journal of Neuroscience 9, 1 (2021).
Seney ML, Kim SM, Glausier JR, Hildebrand MA, Xue X, Zong W, Wang J, Shelton MA, Phan BN, Srinivasan C, Pfenning AR, Tseng GC, Lewis DA, Freyberg Z, Logan RW, “Transcriptional alterations in dorsolateral prefrontal cortex and nucleus accumbens implicate neuroinflammation and synaptic remodeling in opioid use disorder”. Biological Psychiatry 12, 6 (2021).
Xue X, Zong W, Glausier JR, Kim SM, Shelton MA, Phan BN, Srinivasan C, Pfenning AR, Tseng GC, Lewis DA, Seney ML, Logan RW, “Molecular rhythm alterations in prefrontal cortex and nucleus accumbens associated with opioid use disorder”. Translational Psychiatry 12, 123 (2022).
Neurogenomics Laboratory